In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein

Abstract excerpt

Since the start of the pandemic, SARS-CoV-2 has already infected more than 250 million people globally, with more than five million fatal cases and huge socio-economic losses. In addition to corticosteroids, and antiviral drugs like remdesivir, various immunotherapies including monoclonal antibodies (mAbs) to S protein of SARS-CoV-2 have been investigated to treat COVID-19 patients. These mAbs were initially...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to SARS-CoV-2 and COVID-19 Research
• Share to Transgenic Plants and Applications
• Share to vaccines and immunoinformatics approaches